Weight loss effect of glucagon-like peptide-1 mimetics on obese/overweight adults without diabetes: A systematic review and meta-analysis of randomized controlled trials

J Diabetes. 2015 May;7(3):329-39. doi: 10.1111/1753-0407.12198. Epub 2014 Sep 10.


Background: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) benefit weight maintenance for diabetic patients. We performed a systematic review to evaluate its weight loss effect on obese/overweight patients without diabetes in randomized controlled trials (RCTs).

Methods: Literature updated to May 5, 2014 from Cochrane Library, MEDLINE, EMBASE and reference lists from relevant articles were identified. RCTs with GLP-1 mimetics treating obese/overweight adults without diabetes for at least 12 weeks were assessed. Studies lacking primary measurements were excluded. Three authors extracted data independently. Either fixed-effect or random-effect models were used to calculate weighted mean differences (WMDs), combined relative risks (RR) and 95% confidence interval (CI) in meta-analyses. Intertrial heterogeneity across studies was examined by I(2) and Q statistics.

Results: A total of 1345 individuals retrieved from eight studies were involved and all included trials were of mild-to-moderate bias risks. Participants in GLP-1RA groups achieved a larger weight loss than those in control groups (-2.85 kg, 95%CI -3.55 to -2.14), and liraglutide may work in a dose-dependent fashion. GLP-1RAs also reduced body mass index (BMI) and waist circumferences (WC) and benefited systolic blood pressure and triglyceride regulation. But GLP-1RAs were associated with increased nausea and vomiting events.

Conclusions: GLP-1 mimetics induce a weight loss in addition to BMI and WC reduction in obese/overweight adults without diabetes. Further long-term randomized trials and basic studies are required to investigate the mechanisms.

Keywords: glucagon-like peptide-1 mimetics; meta-analysis; non-diabetes; obesity; weight loss; 关键词:胰高血糖素样肽-1类似物,meta分析,非糖尿病,肥胖,减重。.

Publication types

  • Meta-Analysis
  • Review
  • Systematic Review

MeSH terms

  • Adult
  • Biomimetics
  • Glucagon-Like Peptide 1 / therapeutic use*
  • Humans
  • Hypoglycemic Agents / therapeutic use*
  • Obesity / drug therapy*
  • Overweight / drug therapy*
  • Randomized Controlled Trials as Topic
  • Receptors, Glucagon / agonists*
  • Weight Loss / drug effects*


  • Hypoglycemic Agents
  • Receptors, Glucagon
  • Glucagon-Like Peptide 1